Breaking News

Cybin Initiates GMP Production of CYB003 for Phase III Trial

Solid dosage capsule form designed to be stable, dose flexible, patient-friendly, and commercially scalable, to be evaluated in a potential Phase 3 trial.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cybin Inc., a clinical-stage biopharmaceutical company developing new psychedelic-based treatment options for mental healthcare, has initiated preparations for good manufacturing practices (GMP) production of a capsule formulation of CYB003, its deuterated psilocybin analog in development for the potential treatment of Major Depressive Disorder (MDD).   The company has developed a robust solid dosage capsule form of CYB003 designed to be stable, dose flexible, patient-friendly, and commerciall...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters